Page 181 - Haematologica Vol. 109 - July 2024

ARTICLE - ASCT in refractory or early relapsed DLBCL
A.M. Tun et al.
vs chimeric antigen receptor T-cell therapy for relapsed DLBCL
in partial remission. Blood. 2022;139(9):1330-1339.
29. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison
of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490-3496.
30. Hoffmann MS, Hunter BD, Cobb PW, Varela JC, Munoz J. Overcoming barriers to referral for chimeric antigen receptor T-cell therapy in patients with relapsed/refractory diffuse large B-cell lymphoma. Transplant Cell Ther. 2023;29(7):440-448.
31. Mailankody S, Matous J V, Chhabra S, et al. Allogeneic BCMA- targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med. 2023;29(2):422-429.
32. Shadman M, Wooahn K, Kaur M, et al. Autologous transplant (auto-HCT) is associated with improved clinical outcomes compared to CAR-T therapy in patients (pts) with large B-cell lymphoma (LBCL) achieving a complete remission. Blood. 2023;142(Suppl 1):781.
33. Jallouk AP, Gouni S, Westin J, et al. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica. 2023;108(4):1163-1167.
34. Wudhikarn K, Tomas AA, Flynn JR, et al. Low toxicity and excellent outcomes in DLBCL patients without residual lymphoma at the time of CD19 CAR T cell therapy. Blood Adv.
2023;7(13):3192-3198.
35. Di Blasi R, Le Gouill S, Bachy E, et al. Outcomes of patients with
aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis. Blood. 2022;140(24):2584-2593.
36. Costa LJ, Maddocks K, Epperla N, et al. Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies. Am J Hematol. 2017;92(2):161-170.
37. Herrera AF, Mei M, Low L, et al. Relapsed or refractory double- expressor and double-hit lymphomas have inferior progression- free survival after autologous stem-cell transplantation. J Clin Oncol. 2017;35(1):24-31.
38. Tun AM, Ansell SM. Immunotherapy in Hodgkin and non- Hodgkin lymphoma: innate, adaptive and targeted immunological strategies. Cancer Treat Rev. 2020;88:102042.
39. Herrera AF, Chen L, Crombie JL, et al. Polatuzumab vedotin combined with R-ICE (PolaR-ICE) as second-line therapy in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2022;140(Suppl 1):1065-1067.
40. Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231.
41. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2022;41(12):2238-2247.
Haematologica | 109 July 2024
2195